ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
This site is part of the Siconnects Division of Sciinov Group
This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.
ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR
22 Jan, 2025
First-in-Class Anti-Necrotic Therapeutic set to initiate clinical trials for kidney disease and accelerated aging in 2025
LinkGevity, an AI-driven drug discovery company focused on age-related diseases and longevity, today announces it has been selected for the prestigious KQ Labs Programme, delivered by the Francis Crick Institute, Europe’s largest biomedical research centre.
The KQ Labs Programme provides participants with an equity investment, and access to an advanced global scientific network. Only 10 startups are chosen annually, after a rigorous due diligence process, for this highly selective initiative that is aimed at propelling world class healthcare innovations forward. LinkGevity’s therapeutic data, innovative approach and scientific leadership secured its place in this elite cohort.
Pioneering a New Paradigm in Drug Discovery
Dr Carina Kern, CEO and co-founder of LinkGevity, said: “Being selected for the KQ Labs Programme is a tremendous honour. This programme will be pivotal to our plans, which include initiating a clinical trial for kidney disease, the 9th leading cause of death globally according to the WHO. What is additionally exciting is that the kidney provides an accelerated aging model to validate this drug as a candidate to treat aging more broadly – paving the way for a potentially landmark trial”.
Serena Kern-Libera, LinkGevity’s COO and co-founder, added: “We are thrilled to be selected for the prestigious KQ Labs Programme, a recognition that underscores the growing excitement around our innovative Anti-Necrotic therapeutic. Building on the momentum from our successful inclusion in the NASA/Microsoft Space-H programme- where we were selected for the potential of our drug to alleviate accelerated aging in astronauts- being part of the wider Francis Crick Institute ecosystem will help propel our research”.